vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and StoneX Group Inc. (SNEX). Click either name above to swap in a different company.
StoneX Group Inc. is the larger business by last-quarter revenue ($1.2B vs $708.5M, roughly 1.7× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 11.6%, a 7.5% gap on every dollar of revenue. On growth, StoneX Group Inc. posted the faster year-over-year revenue change (81.0% vs 32.0%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-1.3B). Over the past eight quarters, StoneX Group Inc.'s revenue compounded faster (53.5% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
StoneX Group Inc. is an American financial services company. The company operates in six areas: commercial hedging, global payments, securities, physical commodities, foreign exchange and clearing and execution services (CES).
MEDP vs SNEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.2B |
| Net Profit | $135.1M | $139.0M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 15.4% |
| Net Margin | 19.1% | 11.6% |
| Revenue YoY | 32.0% | 81.0% |
| Net Profit YoY | 15.5% | 63.3% |
| EPS (diluted) | $4.65 | $2.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $1.2B | ||
| Q3 25 | $659.9M | $32.7B | ||
| Q2 25 | $603.3M | $851.2M | ||
| Q1 25 | $558.6M | $820.4M | ||
| Q4 24 | $536.6M | $663.1M | ||
| Q3 24 | $533.3M | $31.1B | ||
| Q2 24 | $528.1M | $571.8M | ||
| Q1 24 | $511.0M | $509.2M |
| Q4 25 | $135.1M | $139.0M | ||
| Q3 25 | $111.1M | $85.7M | ||
| Q2 25 | $90.3M | $63.4M | ||
| Q1 25 | $114.6M | $71.7M | ||
| Q4 24 | $117.0M | $85.1M | ||
| Q3 24 | $96.4M | $76.7M | ||
| Q2 24 | $88.4M | $61.9M | ||
| Q1 24 | $102.6M | $53.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 21.6% | 15.4% | ||
| Q3 25 | 21.5% | 0.3% | ||
| Q2 25 | 20.9% | -1.3% | ||
| Q1 25 | 20.3% | -1.0% | ||
| Q4 24 | 23.4% | -3.2% | ||
| Q3 24 | 21.1% | -0.0% | ||
| Q2 24 | 19.9% | -4.7% | ||
| Q1 24 | 20.4% | -2.5% |
| Q4 25 | 19.1% | 11.6% | ||
| Q3 25 | 16.8% | 0.3% | ||
| Q2 25 | 15.0% | 7.4% | ||
| Q1 25 | 20.5% | 8.7% | ||
| Q4 24 | 21.8% | 12.8% | ||
| Q3 24 | 18.1% | 0.2% | ||
| Q2 24 | 16.7% | 10.8% | ||
| Q1 24 | 20.1% | 10.4% |
| Q4 25 | $4.65 | $2.50 | ||
| Q3 25 | $3.86 | $0.72 | ||
| Q2 25 | $3.10 | $1.22 | ||
| Q1 25 | $3.67 | $1.41 | ||
| Q4 24 | $3.67 | $1.69 | ||
| Q3 24 | $3.01 | $2.32 | ||
| Q2 24 | $2.75 | $1.25 | ||
| Q1 24 | $3.20 | $1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $1.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $2.5B |
| Total Assets | $2.0B | $47.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $1.6B | ||
| Q3 25 | $285.4M | $1.6B | ||
| Q2 25 | $46.3M | $1.3B | ||
| Q1 25 | $441.4M | $1.3B | ||
| Q4 24 | $669.4M | $1.4B | ||
| Q3 24 | $656.9M | $1.3B | ||
| Q2 24 | $510.9M | $1.2B | ||
| Q1 24 | $407.0M | $1.3B |
| Q4 25 | $459.1M | $2.5B | ||
| Q3 25 | $293.6M | $2.4B | ||
| Q2 25 | $172.4M | $2.0B | ||
| Q1 25 | $593.6M | $1.9B | ||
| Q4 24 | $825.5M | $1.8B | ||
| Q3 24 | $881.4M | $1.7B | ||
| Q2 24 | $763.6M | $1.6B | ||
| Q1 24 | $671.5M | $1.5B |
| Q4 25 | $2.0B | $47.8B | ||
| Q3 25 | $1.8B | $45.3B | ||
| Q2 25 | $1.6B | $34.3B | ||
| Q1 25 | $1.9B | $31.3B | ||
| Q4 24 | $2.1B | $29.6B | ||
| Q3 24 | $2.1B | $27.5B | ||
| Q2 24 | $1.9B | $25.9B | ||
| Q1 24 | $1.8B | $25.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $-1.3B |
| Free Cash FlowOCF − Capex | $188.1M | $-1.3B |
| FCF MarginFCF / Revenue | 26.6% | -106.4% |
| Capex IntensityCapex / Revenue | 0.6% | 1.3% |
| Cash ConversionOCF / Net Profit | 1.43× | -9.08× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $3.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $-1.3B | ||
| Q3 25 | $246.2M | $3.5B | ||
| Q2 25 | $148.5M | $1.5B | ||
| Q1 25 | $125.8M | $-154.5M | ||
| Q4 24 | $190.7M | $-477.8M | ||
| Q3 24 | $149.1M | $192.6M | ||
| Q2 24 | $116.4M | $-622.1M | ||
| Q1 24 | $152.7M | $784.0M |
| Q4 25 | $188.1M | $-1.3B | ||
| Q3 25 | $235.5M | $3.5B | ||
| Q2 25 | $142.4M | $1.5B | ||
| Q1 25 | $115.8M | $-169.8M | ||
| Q4 24 | $183.0M | $-491.4M | ||
| Q3 24 | $138.5M | $175.9M | ||
| Q2 24 | $103.5M | $-640.5M | ||
| Q1 24 | $147.2M | $766.6M |
| Q4 25 | 26.6% | -106.4% | ||
| Q3 25 | 35.7% | 10.7% | ||
| Q2 25 | 23.6% | 173.3% | ||
| Q1 25 | 20.7% | -20.7% | ||
| Q4 24 | 34.1% | -74.1% | ||
| Q3 24 | 26.0% | 0.6% | ||
| Q2 24 | 19.6% | -112.0% | ||
| Q1 24 | 28.8% | 150.5% |
| Q4 25 | 0.6% | 1.3% | ||
| Q3 25 | 1.6% | 0.1% | ||
| Q2 25 | 1.0% | 1.9% | ||
| Q1 25 | 1.8% | 1.9% | ||
| Q4 24 | 1.4% | 2.1% | ||
| Q3 24 | 2.0% | 0.1% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 1.1% | 3.4% |
| Q4 25 | 1.43× | -9.08× | ||
| Q3 25 | 2.22× | 41.18× | ||
| Q2 25 | 1.65× | 23.52× | ||
| Q1 25 | 1.10× | -2.15× | ||
| Q4 24 | 1.63× | -5.61× | ||
| Q3 24 | 1.55× | 2.51× | ||
| Q2 24 | 1.32× | -10.05× | ||
| Q1 24 | 1.49× | 14.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
SNEX
Segment breakdown not available.
